Affinivax Presents Data for Enhanced Protection Against Serotype 3 in Next-Generation Pneumococcal Vaccine
– Preclinical data show synergistic protective effect of anti-protein and anti-polysaccharide antibodies in a highly virulent model of serotype 3 invasive pneumococcal disease – – Presentation at the 12th International Symposium on Pneumococci and Pneumococcal Diseases – CAMBRIDGE, Mass.–(BUSINESS WIRE)–Affinivax, Inc. (“Affinivax”), a clinical stage biopharmaceutical company pioneering the development of a novel class of … [Read more…]